Price movement over the last 24 hours
Aegon Ltd. vs 22nd Century Group Inc — how do they compare? Aegon Ltd. trades at $8.72 (market cap $12.98B), while 22nd Century Group Inc trades at $4.3 (market cap $1.48M). The key difference: Aegon Ltd. is far larger — about 8770.3× 22nd Century Group Inc's market cap, and Aegon Ltd. pays a 5.3% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| AEG | XXII | |
|---|---|---|
Market Cap | $12.98B | $1.48M |
Sector | Financials | Technology |
52-Week High | $8.79 | $2.04K |
52-Week Low | $6.79 | $3.90 |
Enterprise Value | $14.11B | -$6.75M |
Dividend Yield | 5.3% | — |
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
XXII trades at $4.28, up 6.73% in the last session, amid a bearish technical outlook. The company reported a net loss of $5.05M on $7.05M revenue in 2025, with negative profitability margins. Recent news highlights expansion of its VLN reduced-nicotine cigarettes into California and New York, aiming to capture market share. A 20:1 reverse stock split was executed on June 12, 2026, to adjust the share structure.
The outlook remains speculative with high execution risk; analyst consensus is 75% buy but fundamentals show deep losses. Key risks include sustained negative cash flow, regulatory hurdles for tobacco products, and reliance on financing. Upside depends on successful commercialization of VLN products and achieving profitability.
Trailing returns across standard periods
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →